Gepotidacin's advantage over nitrofurantoin was largest when the organism was not nitrofurantoin-susceptible

Design

Pooled subgroup analysis of two phase 3 randomised trials

Population

Women and girls aged 12+ with uncomplicated UTI in EAGLE-2 and EAGLE-3

Primary outcome

Therapeutic success at test-of-cure (day 10-13)

Effect

Difference +9.6 (susceptible) and +20.8 points (non-susceptible) favouring gepotidacin

A pooled analysis in Clinical Infectious Diseases, published on 28 October 2026, combined the phase 3 EAGLE-2 and EAGLE-3 trials, in which women and girls aged 12 or over with uncomplicated UTI received gepotidacin 1,500 mg or nitrofurantoin 100 mg, both twice daily for five days. Gepotidacin is a triazaacenaphthylene antibacterial, a new class that inhibits bacterial DNA replication by a different mechanism from fluoroquinolones.

With nitrofurantoin-susceptible organisms, therapeutic success (symptoms resolved plus bacteria cleared) favoured gepotidacin by 9.6 points (95% CI 4.1 to 15.2). With non-susceptible organisms the difference was 20.8 points (9.2 to 32.4). In both groups the gain came from microbiological clearance; symptomatic success differences were small and their intervals crossed zero. Results held in subgroups at higher resistance risk, including older women, recurrent UTI, diabetes and ESBL-producing or fluoroquinolone-resistant organisms.

For prescribers, this gives a reasonably clear niche: a new oral option where nitrofurantoin resistance is known or likely. The analysis is industry-sponsored and descriptive, and wider use risks spending a new agent on infections that older drugs treat well. Availability and regulatory status in India are not known to us.

• Consider gepotidacin, where available, for uncomplicated UTI when the organism is nitrofurantoin non-susceptible.
• Keep nitrofurantoin or other first-line agents for susceptible infections, to preserve the newer drug.
• Send a urine culture in recurrent or treatment-failure UTI to guide the choice.
• Check the label for interactions and cautions before prescribing a newly licensed antibacterial.
• Involve local antimicrobial stewardship in deciding its place.

Why it matters

Rising nitrofurantoin and fluoroquinolone resistance leaves few oral options; this defines where a new one helps most.

Don't overread it

A descriptive subgroup analysis of industry trials; symptomatic benefit was not clearly better.

The statistics, in plain English

The non-susceptible group was smaller, so its interval (9.2 to 32.4) is wide. The clinical-success intervals cross zero, meaning symptom resolution was not clearly different; the advantage was in clearing bacteria.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.